Pain J B, Lê M P, Caseris M, Amiel C, Lassel L, Charpentier C, Desnoyer A, Farnoux C, Pialoux G, Descamps D, Peytavin G
AP-HP, Clinical Pharmacology Department, Bichat Hospital, Paris, France.
AP-HP, Clinical Pharmacology Department, Bichat Hospital, Paris, France
Antimicrob Agents Chemother. 2015;59(6):3660-2. doi: 10.1128/AAC.00173-15. Epub 2015 Apr 6.
We describe the pharmacokinetics of dolutegravir (DTG) in a premature neonate after maternal intensification of an antiretroviral (ARV) regimen by adding DTG. During the last 2 weeks of pregnancy, the ARV was tenofovir-emtricitabine, atazanavir-ritonavir, and DTG (50 mg once daily). From the interaction between atazanavir and DTG via CYP3A4 and UGT1A1 and placental efflux transporter inhibition and considering the infant's probable enzymatic immaturity, the DTG elimination half-life was estimated to be 4-fold longer in neonates than in adults.
我们描述了在母亲强化抗逆转录病毒（ARV）方案中添加多替拉韦（DTG）后，一名早产儿体内DTG的药代动力学情况。在妊娠的最后2周，ARV方案为替诺福韦-恩曲他滨、阿扎那韦-利托那韦和DTG（每日一次，50毫克）。鉴于阿扎那韦与DTG通过CYP3A4和UGT1A1相互作用以及胎盘外排转运体抑制作用，同时考虑到婴儿可能存在酶不成熟的情况，估计新生儿体内DTG的消除半衰期比成人长4倍。
